The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Specific targeting of hepatocytes can be achieved using GalNAc-conjugation, such as GalNAc-siRNA or antisense oligonucleotides, which has been successfully used to silence hepatic PCSK9 expression in a clinical trial.
“Specific targeting hepatocytes can be archived using N-acetylgalactosamine (GalNAc)-conjugation, such as GalNAc-siRNA or antisense oligonucleotides (ASOs) (50–52), which has been successfully used to silence hepatic PCSK9 expression in a clinical trial (51).”
From Identification of amino acid residues in the MT-loop of MT1-MMP critical for its ability to cleave low-density lipoprotein receptor (2022) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Self-citationInclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Self-citationPCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Flagged first, then by citations
Research works printed but not linked: 10
- Perreault, 2009, Impact of better adherence to statin agents in the primary prevention of coronary artery disease, Eur J Clin Pharmacol, 65, 1013, 10.1007/s00228-009-0673-0 · DOI
- Nishikido, 2018, Inclisiran for the treatment of dyslipidemia, Expert Opin Investig Drugs, 27, 287, 10.1080/13543784.2018.1442435 · DOI
- Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 · DOI · Paper page
- Ding, 2020, PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1, Cardiovasc Res, 116, 908, 10.1093/cvr/cvz313 · DOI
- Tuñón, 2019, Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology, Cardiovasc Res, 115, 10, 10.1093/cvr/cvy293 · DOI
- Bernelot Moens, 2017, PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia, Eur Heart J, 8, 1584, 10.1093/eurheartj/ehx002 · DOI
- Noto, 2018, Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?, Cardiovasc Res, 114, 1595, 10.1093/cvr/cvy144 · DOI
- Schmidt, 2017, Lancet Diabetes Endocrinol, 97
- Witzigmann, 2016, Variable asialoglycoprotein receptor 1 expression in liver disease: implications for therapeutic intervention, Hepatol Res, 46, 686, 10.1111/hepr.12599 · DOI
- Willoughby, 2018, Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression, Mol Ther, 26, 105, 10.1016/j.ymthe.2017.08.019 · DOI
Cited by
Sorted by citations
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
Wang, M., Alabi, A., Gu, H.-M., Gill, G., Zhang, Z., Jarad, S., Xia, X.-D., Shen, Y., Wang, G.-Q., & Zhang, D.-W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.917238 · Cited by 13
Metadata
- Authors
- Cupido, A. J., & Kastelein, J. J. P.
- Affiliations
- Department of Vascular Medicine, Amsterdam University Medical Centres – location AMC, University of Amsterdam, Amsterdam, The Netherlands
- ORCID
- Cupido, Arjen J
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-07
- Volume
- 116
- Issue
- 11
- Pages
- e136-e139
- ISSN
- 0008-6363
- 1755-3245
- PMC
- PMC7449556
- Cited by
- 44
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
